American Society of Hirudotherapy

Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding

Research article published in The American journal of emergency medicine (2023)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentBrown et al. · The American journal of emergency medicine, 2023

Abstract

BACKGROUND: Andexanet alfa (AA) is approved for reversal of factor Xa inhibitor (FXaI) bleeds; however, there are limited reports of its use for gastrointestinal bleeding (GIB) in real-world populations. The objective of this study was to report real-world utilization and evaluation of the effectiveness of AA for FXaI-associated GIB. METHODS: This retrospective cohort study including consecutive patients receiving AA for FXaI-associated GIB (7/2018-2/2021). Demographics, blood product administration, hemostatic efficacy, rebleeding, thrombosis, and mortality rates were collected. Hemostatic efficacy (HE), based on corrected hemoglobin at 12 h compared to baseline, was categorized as excellent (<10% decrease), good (≤ 20% decrease), or poor (>20% decrease, > 2 units of additional coagulation intervention or death prior to repeat hemoglobin). Comparative transfusion requirements between efficacy groups was assessed by Wilcoxon-Rank test. RESULTS: Twenty-two patients were included (64% male, median (IQR) age 76 years (67, 80). Most patients (59%, n = 13) were on apixaban, and the primary anticoagulation indication was atrial fibrillation (64%, n = 14). Median initial hemoglobin was 7.5 g/dL (IQR 6.4, 8.8) and 50% (n = 11) were upper GIB. Hemostatic efficacy was excellent in 46% (n = 10), good in 23% (n = 5), and poor in 32% (n = 7). There was no statistically significant difference in red blood cells (RBCs) received between those with excellent/good hemostasis (median 2, IQR 1 to 2) and those with poor hemostasis (median 4, IQR 1.5 to 4.5). Two patients (9%) had arterial thrombotic events within 30 days of reversal. CONCLUSION: In this multicenter, single arm, real-world observational analysis of patients with factor Xa inhibitor associated GIB most patients achieved good hemostasis following administration of AA. There was a 9% 30-day thrombotic event rate. The lack of a control group limits the strength of the conclusions that can be drawn from this study.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsHumansMaleFactor Xa InhibitorsRetrospective StudiesGastrointestinal HemorrhageFemaleAgedFactor XaRecombinant ProteinsAged, 80 and overPyrazolesPyridones

Summary

In 22 patients receiving andexanet alfa for factor Xa inhibitor-associated gastrointestinal bleeding, corrected-hemoglobin hemostatic efficacy was excellent in 46%, good in 23% and poor in 32%, with a 9% 30-day arterial thrombotic event rate and no significant difference in red-cell transfusion between efficacy groups.

Context

This retrospective cohort study reported real-world use of andexanet alfa for factor Xa inhibitor–associated gastrointestinal bleeding in 22 consecutive patients (most on apixaban, primarily for atrial fibrillation), finding hemostatic efficacy was excellent in 46%, good in 23%, and poor in 32%, with no statistically significant difference in red-cell transfusion between efficacy groups and a 9% (2 patients) 30-day arterial thrombotic event rate. This contributes to the wider anticoagulant-reversal landscape rather than to leech-secretome science: factor Xa inhibitors and andexanet alfa are not leech-derived agents, but they define the broader antithrombotic context surrounding hirudin-class therapies. Honest caveat: the authors explicitly note this is a small, single-arm, multicenter observational analysis with no control group, which limits the strength of any conclusions, so it documents real-world experience in a handful of patients rather than establishing comparative efficacy, and it has no direct hirudotherapy relevance of its own.

Citation

Reference (Vancouver style)

Brown CS, Mattson AE, Cabrera D, Coelho-Prabhu N, Rabinstein AA, Dettling T, et al. Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding. Am J Emerg Med. 2023;73:1-6. doi:10.1016/j.ajem.2023.07.042. PMID: 37562071

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.